[184 Pages Report] The Anti-Mullerian Hormone Test Market size was estimated at USD 274.26 million in 2023 and expected to reach USD 305.41 million in 2024, at a CAGR 11.46% to reach USD 586.48 million by 2030.
The anti-mullerian hormone (AMH) test is a diagnostic tool healthcare professionals utilize to evaluate ovarian reserve, fertility potential, and reproductive health in women. AMH is a glycoprotein hormone created by the granulosa cells of pre-antral and antral follicles in the ovaries which plays a crucial role in regulating follicular development by inhibiting the recruitment of primordial follicles into the growing pool. Measuring AMH levels provides valuable insights into a woman's ovarian reserve, which directs to the number of eggs that can potentially develop into healthy embryos. The AMH test also has clinical utility in diagnosing polycystic ovary syndrome (PCOS), a common endocrine disorder causing irregular menstrual cycles and increased risk of infertility. AMH testing serves as an invaluable tool for assessing the risk of premature ovarian insufficiency (POI) or early menopause in cancer patients undergoing treatments such as chemotherapy or pelvic radiation therapy. Monitoring AMH levels before, during, and after these therapies help identify individuals at higher risk for POI and guide appropriate measures to preserve their fertility options. Moreover, the rising number of women's health diseases and the growing number of IVF and egg-freezing procedures raised the need for AMH tests. However, inconsistent results of in-home diagnostics kits and unclear reimbursement options significantly impede the adoption of AMH tests. In addition, emerging FDA approval of AMH test in menopausal status and the emerging adoption of automated AMH tests is expected to create tremendous opportunities for market development.
In the Americas, the anti-mullerian hormone test market has experienced substantial growth due to increasing infertility concerns, rising research and development (R&D) efforts, and the surging number of approvals in AMH by the FDA in the recent period. The U.S. and Canada are heading the regional AMH market landscape with product development and increased infertility in women. In Mexico, Argentina, and Brazil, the rapid urbanization process significantly contributes to the fertility decrease, primarily linked to the country's significant social, economic, and political transformations, further contributing to the AMH test market growth. In the Asia-Pacific, the AMH test market is expected to grow significantly due to increasing infertility treatment centers & laboratories, awareness among the population, investment in healthcare & related infrastructure, and supportive government policies for AMH tests. The major economies, including China, Japan, India, Australia, and Singapore, offer positive prospects with increasing demand and adoption of female fertility care. In the EMEA region, the developed European economies represent the advanced landscape, whereas, in the Middle East & Africa, the major economies such as UAE, Saudi Arabia, and South Africa are gradually moving ahead with several developments in the healthcare sector. Moreover, rising governments focus on providing supportive measures and raising awareness and investment from private healthcare, and pharmaceutical companies are expected to expand the market's potential in the EMEA region.
The FPNV Positioning Matrix is pivotal in evaluating the Anti-Mullerian Hormone Test Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Mullerian Hormone Test Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Quest and Proov Collaborate to Bring Novel Home Fertility Test to Women Through questhealth.com
Quest Diagnostics collaborated with Proov to introduce the Proov Confirm PdG test, the first FDA-cleared at-home fertility and hormone test kit available through questhealth.com. The Proov Confirm PdG test is designed to detect pregnanediol glucuronide (PdG) in urine, providing valuable confirmation of ovulation. [Published On: 2023-07-06]
LifeCell Launches Advanced Self Collection Healthcare Services
LifeCell International launched testing and preservation kits for various reproductive, sexual, women's, and baby health services. These kits are specifically designed to ensure utmost privacy and convenience for individuals. LifeCell International offers self-collection testing kits, which allow individuals to privately and conveniently test for various conditions without the need for a doctor's prescription or visiting a lab. The company launched the Perimenopause Test, an FDA-cleared AMH blood test that accurately determines the onset of a woman's final menstrual cycle. [Published On: 2023-06-21]
Eli Raises USD 5 Million to Make At-Home Hormone Testing for Women more Accessible
Eli, a healthtech startup based in Montréal, has successfully secured USD 5 million CAD in seed funding for its innovative hormone testing solutions. Eli's ground-breaking product aims to simplify hormone measurement by utilizing a three-step process: collecting a small saliva sample, inserting it into a palm-sized reader, and receiving results through a mobile app. With the newly raised funds, Eli plans to finalize product development, proceed with clinical validation, and obtain necessary regulatory approvals before the official launch. [Published On: 2023-04-04]
The report delves into recent significant developments in the Anti-Mullerian Hormone Test Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Ansh Labs, Athenese-Dx, BioMérieux SA, Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., Cusabio Technology LLC, Danaher Corporation, Doctorcall Limited, Eagle Biosciences, Inc., Elabscience, Inc., enQuire Bio, LLC, F. Hoffmann-La Roche AG, Fertility 2 U Ltd, Goldsite Diagnostics Inc., Kamiya Biomedical Co, LifeSpan BioSciences, Inc., London Gynaecology Ltd., Meridian Life Science, Inc. by SD Biosensor, Monobind Inc., Tosoh Corporation, Vitall by Healthy Human Labs Ltd., Vitrosens Biotechnology, and Walk-In Lab, LLC.
This research report categorizes the Anti-Mullerian Hormone Test Market to forecast the revenues and analyze trends in each of the following sub-markets:
- POC Testing
- Self-check Kits
- ELISA Kits
- Rapid Test Kit
- Commercial Labs
- Research & development
- Offline Channels
- Online Channels
- United States
- New York
- South Korea
- Europe, Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- United Kingdom
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Anti-Mullerian Hormone Test Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Mullerian Hormone Test Market?
- What are the technology trends and regulatory frameworks in the Anti-Mullerian Hormone Test Market?
- What is the market share of the leading vendors in the Anti-Mullerian Hormone Test Market?
- Which modes and strategic moves are suitable for entering the Anti-Mullerian Hormone Test Market?
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Anti-Mullerian Hormone Test Market, by Product
- Anti-Mullerian Hormone Test Market, by End-User
- Anti-Mullerian Hormone Test Market, by Distribution
- Anti-Mullerian Hormone Test Market, by Use
- Americas Anti-Mullerian Hormone Test Market
- Asia-Pacific Anti-Mullerian Hormone Test Market
- Europe, Middle East & Africa Anti-Mullerian Hormone Test Market
- Competitive Landscape
- Competitive Portfolio
- Abbexa Ltd.
- Ansh Labs
- BioMérieux SA
- Chengdu VACURE Biotechnology Co., Ltd.
- CTK Biotech, Inc.
- Cusabio Technology LLC
- Danaher Corporation
- Doctorcall Limited
- Eagle Biosciences, Inc.
- Elabscience, Inc.
- enQuire Bio, LLC
- F. Hoffmann-La Roche AG
- Fertility 2 U Ltd
- Goldsite Diagnostics Inc.
- Kamiya Biomedical Co
- LifeSpan BioSciences, Inc.
- London Gynaecology Ltd.
- Meridian Life Science, Inc. by SD Biosensor
- Monobind Inc.
- Tosoh Corporation
- Vitall by Healthy Human Labs Ltd.
- Vitrosens Biotechnology
- Walk-In Lab, LLC